Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin versus metformin for insulin resistance in women with polycystic ovary syndrome
IRCT20250703066346N1Phase 3Completed
- Sponsor
- Islamic Azad University
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of empagliflozin and metformin in polycystic ovary syndrome (PCOS) and diabetes mellitus (DM) (2 arms), sponsored by Islamic Azad University. Primary endpoint: Fasting blood sugar. Started Oct 2025; status: completed.
02
Drugs
empagliflozinmetformin
03
Conditions
polycystic ovary syndrome (PCOS)diabetes mellitus (DM)
Beyond the preview
Go deeper on IRCT20250703066346N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20250703066346N1.